Leqembi (Lecanemab)

Lecanemab is a monoclonal antibody that binds selectively to soluble aggregated amyloid‑beta protofibrils. By attaching to these aggregates, it promotes their clearance from the brain, decreasing amyloid plaque formation and the downstream neuroinflammatory cascade associated with Alzheimer’s disease.

The specific dose and infusion schedule are determined by the prescribing clinician based on the patient’s condition, weight, and clinical guidelines. Typically, the medication is administered by intravenous infusion at intervals recommended by the treating physician.

Safety data for lecanemab in pregnancy and lactation are limited. The product should be used only if the potential benefits outweigh the potential risks to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Leqembi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Leqembi (lecanemab) and other agents such as aducanumab or donanemab share the goal of reducing amyloid burden, but they differ in target specificity, dosing frequency, and safety profiles. Leqembi uniquely targets soluble protofibrils and has demonstrated a lower incidence of certain ARIA events in clinical trials compared with some alternatives.

Leqembi must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If temperature excursions occur, consult the product’s stability guidelines before use.

Leqembi is given as an intravenous infusion by a qualified healthcare professional. The infusion is performed in a clinical setting where vital signs can be monitored, and emergency equipment is available to manage potential infusion‑related reactions.

The most serious risks include amyloid‑related imaging abnormalities (ARIA) such as cerebral edema or microhemorrhage, severe hypersensitivity reactions including anaphylaxis, and rare cases of encephalitis. Patients should be monitored closely with imaging and clinical assessments throughout treatment.

Leqembi is contraindicated in individuals with known hypersensitivity to lecanemab or any of its excipients. Caution is also advised for patients with uncontrolled bleeding disorders, active infections, or those who have experienced severe ARIA with prior amyloid‑targeting therapies.